Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02856854 · ClinicalTrials.gov registry record · Phase 1
A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine
A Phase 1 study, sponsored by Embera NeuroTherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02856854 is a Phase 1 study that has completed, run by Embera NeuroTherapeutics. The registered enrollment target is 18 participants.
The verdict
NCT02856854, a Phase 1 study, has completed, sponsored by Embera NeuroTherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only). This Phase 1b cocaine interaction study is being conducted in order to assess the safety and PK of EMB-001 and cocaine in combination.
Interventions
- DRUG Placebo
- DRUG EMB-001
- DRUG Saline IV
- DRUG Cocaine IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-07 |
| Est. Completion | 2017-07-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02856854
The ClinicalTrials.gov registry entry for NCT02856854 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Embera NeuroTherapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02856854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02856854 about?
NCT02856854 is a clinical study titled "A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine". EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only). This Phase 1b cocaine interaction study is being conducted in order to assess the...
What is the current status of trial NCT02856854?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2016-07. Estimated completion is 2017-07-25.
What interventions are being tested in trial NCT02856854?
The interventions under investigation include: Placebo (DRUG), EMB-001 (DRUG), Saline IV (DRUG), Cocaine IV (DRUG).
Who is sponsoring clinical trial NCT02856854?
This trial is sponsored by Embera NeuroTherapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.